# Gintonin Binds to Reduced LPA4 Receptor Subtype in Human Cortical Neurons in Alzheimer’s Disease Brains

## TL;DR

Gintonin, a compound from ginseng, binds to LPA4 receptors in brain neurons, and these receptors are reduced in Alzheimer's disease, suggesting a new target for treatment.

## Contribution

This study identifies LPA4 as the specific receptor subtype targeted by gintonin in human cortical neurons and shows its reduced expression in Alzheimer’s disease.

## Key findings

- Fluorescent gintonin selectively binds to human cortical neurons, not glial cells.
- Gintonin-binding sites co-localize with the LPA4 receptor subtype in cortical neurons.
- LPA4 receptor expression is significantly reduced in Alzheimer’s disease patient brains.

## Abstract

Ginseng, a traditional herbal medicine with a long history of use, is known to support human health, particularly by influencing brain function. Recent studies have identified gintonin, a lysophosphatidic acid (LPA) receptor ligand derived from ginseng, as a key bioactive. However, the specific LPA receptor subtypes targeted by gintonin in the human brain to exert its anti-Alzheimer’s (AD) effects remain unclear. This study aimed to elucidate the LPA receptor subtype targeted by gintonin in the human cortex. Using a fluorescent gintonin conjugate, we investigated receptor binding in cortical samples from healthy individuals (n = 4) and AD patients (n = 4). Our results demonstrated that fluorescent gintonin selectively binds to human cortical neurons rather than glial cells and that gintonin-binding sites are co-localized with the LPA4 receptor subtype. Furthermore, the expression of LPA4 receptors was significantly reduced in the cortical neurons of AD patients. These results suggest that the LPA4 receptor may serve as a novel histopathological marker for AD and represent a promising therapeutic target for gintonin-based prevention and treatment strategies.